Parkinson's Disease - Treatment Options, Symptoms, Causes & Diagnosis from MedifocusHealth

Parkinson's Disease > What Your Doctor is Reading About Parkinson's Disease > Review Articles

Review Articles

1. Treatment options in the modern management of Parkinson disease.

Author: Schapira AH;
Institution: University Department of Clinical Neurosciences, Institute of Neurology, University College London, England. a.schapira@medsch.ucl.ac.uk
Journal: Arch Neurol. 2007 Aug;64(8):1083-8.

2. Chinese herbs and herbal extracts for neuroprotection of dopaminergic neurons and potential therapeutic treatment of Parkinson's disease.

Author: Chen LW; Wang YQ; Wei LC; Shi M; Chan YS;
Institution: Institute of Neurosciences, The Fourth Military Medical University, Xi'an 710032, PR China. lwchen@pub.xaonline.com
Journal: CNS Neurol Disord Drug Targets. 2007 Aug;6(4):273-81.
Abstract URL: Click here to view abstract

3. Gene therapy for Parkinson's disease.

Author: Mochizuki H;
Institution: Department of Neurology, Research Institute for Diseases of Old Age, Juntendo University, Hongo, Bunkyo, Tokyo, Japan. hideki@med.juntendo.ac.jp
Journal: Expert Rev Neurother. 2007 Aug;7(8):957-60.
Abstract URL: Click here to view abstract

4. Parkinson's disease.

Author: Clarke CE;
Institution: Department of Neurology, City Hospital, Sandwell and West Birmingham Hospitals NHS Trust, Birmingham B18 7QH.
Journal: BMJ. 2007 Sep 1;335(7617):441-5.

5. Management of non-motor symptoms in advanced Parkinson disease.

Author: Truong DD; Bhidayasiri R; Wolters E;
Institution: The Parkinson's and Movement Disorder Institute, 9940 Talbert Avenue, Fountain Valley, CA 92708, USA. dtruong@pmdi.org
Journal: J Neurol Sci. 2008 Mar 15;266(1-2):216-28. Epub 2007 Sep 4.
Abstract URL: Click here to view abstract

6. Apomorphine therapy in Parkinson's disease: a review.

Author: Haq IU; Lewitt PA; Fernandez HH;
Institution: Movement Disorders Program, University of Florida, Department of Neurology/McKnight Brain Institute, 100 S. Newell Drive, PO Box 100236, Gainesville, Florida 32610-0236, USA. ihtsham.haq@neurology.ufl.edu
Journal: Expert Opin Pharmacother. 2007 Nov;8(16):2799-809.
Abstract URL: Click here to view abstract

7. The future of cell therapies in the treatment of Parkinson's disease.

Author: Goya RL; Kuan WL; Barker RA;
Institution: Cambridge Centre for Brain Repair, Forvie Site, Robinson Way, Cambridge CB2 2PY, UK. rl342@cam.ac.uk
Journal: Expert Opin Biol Ther. 2007 Oct;7(10):1487-98.
Abstract URL: Click here to view abstract

8. Motor complications in Parkinson disease: clinical manifestations and management.

Author: Bhidayasiri R; Truong DD;
Institution: Chulalongkorn Comprehensive Movement Disorders Center, Division of Neurology, Chulalongkorn University Hospital, Bangkok 10330, Thailand. rbh1@ucla.edu
Journal: J Neurol Sci. 2008 Mar 15;266(1-2):204-15. Epub 2007 Sep 27.
Abstract URL: Click here to view abstract

9. Assessment of the progression of Parkinson's disease: a metabolic network approach.

Author: Eckert T; Tang C; Eidelberg D;
Institution: Center for Neurosciences, Feinstein Institute for Medical Research, North Shore-Long Island Jewish Health System, Manhasset, NY 11030, USA.
Journal: Lancet Neurol. 2007 Oct;6(10):926-32.
Abstract URL: Click here to view abstract

10. Zonisamide for the treatment of Parkinson's disease.

Author: Miwa H;
Institution: Wakayama Medical University, Department of Neurology, 811-1 Kimiidera, Wakayama city, Wakayama 641-8510, Japan. h-miwa@wakayama-med.ac.jp
Journal: Expert Rev Neurother. 2007 Sep;7(9):1077-83.
Abstract URL: Click here to view abstract

11. Deep brain stimulation for the treatment of atypical parkinsonism.

Author: Shih LC; Tarsy D;
Institution: Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA.
Journal: Mov Disord. 2007 Nov 15;22(15):2149-55.
Abstract URL: Click here to view abstract

12. Sialorrhea in Parkinson's disease: a review.

Author: Chou KL; Evatt M; Hinson V; Kompoliti K;
Institution: Department of Clinical Neurosciences, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA. Kelvin_Chou@brown.edu
Journal: Mov Disord. 2007 Dec;22(16):2306-13.
Abstract URL: Click here to view abstract

13. Parkinson-related dementias.

Author: Boeve BF;
Institution: Division of Behavioral Neurology, Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA. bboeve@mayo.edu <bboeve@mayo.edu>
Journal: Neurol Clin. 2007 Aug;25(3):761-81, vii.
Abstract URL: Click here to view abstract

14. Role of deep brain stimulation targeted to the pedunculopontine nucleus in Parkinson's disease.

Author: Kenney C; Fernandez HH; Okun MS;
Institution
Journal: Expert Rev Neurother. 2007 Jun;7(6):585-9.

15. Botulinum toxin in the treatment of tremors, dystonias, sialorrhea and other symptoms associated with Parkinson's disease.

Author: Sheffield JK; Jankovic J;
Institution: Department of Neurology, Baylor College of Medicine, Parkinson's Disease Center & Movement Disorders Clinic, 6550 Fannin, Suite 1801, Houston, TX 77030, USA. jksheffi@bcm.edu
Journal: Expert Rev Neurother. 2007 Jun;7(6):637-47.
Abstract URL: Click here to view abstract

16. Autosomal dominant Parkinson's disease and the route to new therapies.

Author: Morris HR;
Institution: School of Medicine, Cardiff University, CF14 4XN, Wales. morrishr@cf.ac.uk
Journal: Expert Rev Neurother. 2007 Jun;7(6):649-56.
Abstract URL: Click here to view abstract

17. Genetics of Parkinson's disease and parkinsonism.

Author: Douglas MR; Lewthwaite AJ; Nicholl DJ;
Institution: University of Birmingham Medical School, Vincent Drive, Edgbaston, Birmingham, B15 2TT, UK. m.r.douglas@blueyonder.co.uk
Journal: Expert Rev Neurother. 2007 Jun;7(6):657-66.
Abstract URL: Click here to view abstract

18. Occupational therapy for patients with Parkinson's disease.

Author: Dixon L; Duncan D; Johnson P; Kirkby L; O'Connell H; Taylor H; Deane KH;
Institution
Journal: Cochrane Database Syst Rev. 2007 Jul 18;(3):CD002813.
Abstract URL: Click here to view abstract

19. Cell-replacement and gene-therapy strategies for Parkinson's and Alzheimer's disease.

Author: Korecka JA; Verhaagen J; Hol EM;
Institution: Netherlands Institute for Neuroscience, Royal Netherlands Academy of Arts and Sciences, Meibergdreef 47, 1105 BA, Amsterdam, The Netherlands.
Journal: Regen Med. 2007 Jul;2(4):425-46.
Abstract URL: Click here to view abstract

20. Rotigotine transdermal patch in the treatment of Parkinson's disease and restless legs syndrome.

Author: Kenney C; Jankovic J;
Institution: Parkinson's disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, 6550 Fannin, Suite 1801, Houston, Texas 77030, USA. kenney@bcm.edu
Journal: Expert Opin Pharmacother. 2007 Jun;8(9):1329-35.
Abstract URL: Click here to view abstract

21. Management of the behavioral aspects of Parkinson's disease.

Author: Borek LL; Chou KL; Friedman JH;
Institution: Neurohealth Alzheimer's Disease and Movement Disorders Center, and Department of Geriatric Psychiatry, Butler Hospital, Warren Alpert Medical School of Brown University, RI, USA. leolisa@yahoo.com
Journal: Expert Rev Neurother. 2007 Jun;7(6):711-25.
Abstract URL: Click here to view abstract

22. Intervening in the neuropsychiatric features of Parkinson's disease.

Author: Weintraub D; Stern MB;
Institution: University of Pennsylvania School of Medicine, Department of Psychiatry, 3535 Market Sreet, Room 3003, Philadelphia, PA 19104, USA. weintrau@mail.med.upenn.edu
Journal: Expert Rev Neurother. 2007 Jun;7(6):699-710.
Abstract URL: Click here to view abstract

23. Stem cell therapy for Parkinson's disease.

Author: Takahashi J;
Institution: Kyoto University, Department of Biological Repair, Institute for Frontier Medical Sciences, Sakyo-ku, Kyoto 606-8507, Japan. jbtaka@frontier.kyoto-u.ac.jp
Journal: Expert Rev Neurother. 2007 Jun;7(6):667-75.
Abstract URL: Click here to view abstract

24. Frontiers in the surgical treatment of Parkinson's disease.

Author: Remple MS; Sarpong Y; Neimat JS;
Institution: Department of Neurological Surgery, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Journal: Expert Rev Neurother. 2008 Jun;8(6):897-906.
Abstract URL: Click here to view abstract

25. Deep brain stimulation for Parkinson's disease.

Author: Limousin P; Martinez-Torres I;
Institution: Unit of Functional Neurosurgery, Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, University College London, London, England, United Kingdom. p.limousin@ion.ac.uk
Journal: Neurotherapeutics. 2008 Apr;5(2):309-19.
Abstract URL: Click here to view abstract

26. Treatment of Parkinson's disease with trophic factors.

Author: Peterson AL; Nutt JG;
Institution: Parkinsons Disease Research, Educational and Clinical Center, Portland Veteran's Administration Medical Center, Portland, Oregon 97239, USA.
Journal: Neurotherapeutics. 2008 Apr;5(2):270-80.
Abstract URL: Click here to view abstract

27. Spheramine for treatment of Parkinson's disease.

Author: Stover NP; Watts RL;
Institution: Department of Neurology, The University of Alabama at Birmingham, Birmingham, Alabama 35294, USA. npstover@uab.edu
Journal: Neurotherapeutics. 2008 Apr;5(2):252-9.
Abstract URL: Click here to view abstract

28. Protection against Parkinson's disease progression: clinical experience.

Author: LeWitt PA; Taylor DC;
Institution: Department of Neurology, Henry Ford Hospital, Detroit, Michigan, USA. palewitt@ameritech.net
Journal: Neurotherapeutics. 2008 Apr;5(2):210-25.
Abstract URL: Click here to view abstract

29. Current status of symptomatic medical therapy in Parkinson's disease.

Author: Factor SA;
Institution: Department of Neurology, Emory University School of Medicine, 1841 Clifton Road NE, Atlanta, Georgia 30329, USA. sfactor@emory.edu
Journal: Neurotherapeutics. 2008 Apr;5(2):164-80.
Abstract URL: Click here to view abstract

30. Depressive symptoms in Parkinson's disease.

Author: Lemke MR;
Institution: Department of Psychiatry, University of Kiel, Kiel, Germany. m.lemke@alsterdorf.de
Journal: Eur J Neurol. 2008 Apr;15 Suppl 1:21-5.
Abstract URL: Click here to view abstract

31. Non-motor symptoms in Parkinson's disease.

Author: Poewe W;
Institution: Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria. werner.poewe@i-med.ac.at
Journal: Eur J Neurol. 2008 Apr;15 Suppl 1:14-20.
Abstract URL: Click here to view abstract

32. Noninvasive brain stimulation for Parkinson's disease and dystonia.

Author: Wu AD; Fregni F; Simon DK; Deblieck C; Pascual-Leone A;
Institution: Department of Neurology, University of California, Los Angeles, California 90095, USA.
Journal: Neurotherapeutics. 2008 Apr;5(2):345-61.
Abstract URL: Click here to view abstract

33. Parkinson's disease--Part 1: Pathophysiology, symptoms, burden, diagnosis, and assessment.

Author: Weintraub D; Comella CL; Horn S;
Institution: University of Pennsylvania, Philadelphia, PA, USA.
Journal: Am J Manag Care. 2008 Mar;14(2 Suppl):S40-8.
Abstract URL: Click here to view abstract

34. Speech and swallowing disorders in Parkinson disease.

Author: Sapir S; Ramig L; Fox C;
Institution: Department of Communication Sciences and Disorders, Faculty of Social Welfare and Health Sciences, University of Haifa, Haifa, Israel. sapir@research.haifa.ac.il
Journal: Curr Opin Otolaryngol Head Neck Surg. 2008 Jun;16(3):205-10.
Abstract URL: Click here to view abstract

35. Management for motor and non-motor complications in late Parkinson's disease.

Author: Chan DK; Cordato DJ; O'Rourke F;
Institution: University of New South Wales, and Department of Aged Care and Rehabilitation, Bankstown-Lidcombe Hospital, Australia.
Journal: Geriatrics. 2008 May;63(5):22-7.
Abstract URL: Click here to view abstract

36. Dopamine agonist therapy in early Parkinson's disease.

Author: Stowe RL; Ives NJ; Clarke C; van Hilten J; Ferreira J; Hawker RJ; Shah L; Wheatley K; Gray R;
Institution: University of Birmingham Clinical Trials Unit, Division of Medical Sciences, Robert Aitken Institute, Edgbaston, Birmingham, UK, B15 2TT.
Journal: Cochrane Database Syst Rev. 2008 Apr 16;(2):CD006564.
Abstract URL: Click here to view abstract

37. Dopamine agonists in Parkinson's disease.

Author: Yamamoto M; Schapira AH;
Institution: Department of Neurology, Kagawa, Prefectural Central Hospital, Takamatsu, Japan.
Journal: Expert Rev Neurother. 2008 Apr;8(4):671-7.
Abstract URL: Click here to view abstract

38. Subthalamic nucleus stimulation in Parkinson's disease: the other side of the medallion.

Author: Temel Y;
Institution: Department of Neuroscience, Maastricht University, Maastricht, The Netherlands. y.temel@np.unimaas.nl
Journal: Exp Neurol. 2008 Jun;211(2):321-3. Epub 2008 Mar 7.

39. Parkinson's disease--Part 3: Neuropsychiatric symptoms.

Author: Weintraub D; Comella CL; Horn S;
Institution: Department of Psychiatry and Neurology, University of Pennsylvania, 3615 Chestnut St, Philadelphia, PA 19104, USA. wintrau@upenn.edu
Journal: Am J Manag Care. 2008 Mar;14(2 Suppl):S59-69.
Abstract URL: Click here to view abstract

40. Parkinson's disease--Part 2: Treatment of motor symptoms.

Author: Weintraub D; Comella CL; Horn S;
Institution: Department of Neurological Sciences, University of Pennsylvania, 330 S 9th St, Philadelphia, PA 19107, USA.
Journal: Am J Manag Care. 2008 Mar;14(2 Suppl):S49-58.
Abstract URL: Click here to view abstract

41. Progress in neuroprotection in Parkinson's disease.

Author: Schapira AH;
Institution: University Department of Clinical Neurosciences, Institute of Neurology, University College London, London, UK. a.schapira@medsch.ucl.ac.uk
Journal: Eur J Neurol. 2008 Apr;15 Suppl 1:5-13.
Abstract URL: Click here to view abstract

42. Neurotrophic factors as a therapeutic target for Parkinson's disease.

Author: Evans JR; Barker RA;
Institution: University of Cambridge, Cambridge Centre for Brain Repair, Department of Clinical Neuroscience, UK. jre24@cam.ac.uk
Journal: Expert Opin Ther Targets. 2008 Apr;12(4):437-47.
Abstract URL: Click here to view abstract

43. Potential therapeutic targets for Parkinson's disease.

Author: Stoessl J;
Institution: University of British Columbia and Vancouver Coastal Health, Pacific Parkinson's Research Centre & National Parkinson Foundation Centre of Excellence, 2221 Wesbrook Mall, Vancouver, BC, V6T 2B5, Canada. jstoessl@interchange.ubc.ca.
Journal: Expert Opin Ther Targets. 2008 Apr;12(4):425-36.
Abstract URL: Click here to view abstract

44. The effectiveness of exercise interventions for people with Parkinson's disease: a systematic review and meta-analysis.

Author: Goodwin VA; Richards SH; Taylor RS; Taylor AH; Campbell JL;
Institution: Primary Care Research Group, Peninsula Medical School, Exeter, United Kingdom. victoria.goodwin@pms.ac.uk
Journal: Mov Disord. 2008 Apr 15;23(5):631-40.
Abstract URL: Click here to view abstract

45. CBT for the treatment of depression in Parkinson's disease: a promising nonpharmacological approach.

Author: Dobkin RD; Menza M; Bienfait KL;
Institution: Department of Psychiatry, UMDNJ/Robert Wood Johnson Medical School, 675 Hoes Lane, Room D-317, Piscataway, NJ 08854, USA. dobkinro@umdnj.edu
Journal: Expert Rev Neurother. 2008 Jan;8(1):27-35.
Abstract URL: Click here to view abstract

46. Role of tolcapone in the treatment of Parkinson's disease.

Author: Leegwater-Kim J; Waters C;
Institution: Lahey Clinic, Department of Neurology, 41 Mall Road, Burlington, MA 01805, USA. leegwa00@lahey.org
Journal: Expert Rev Neurother. 2007 Dec;7(12):1649-57.
Abstract URL: Click here to view abstract

47. Drug Insight: impulse control disorders and dopamine therapies in Parkinson's disease.

Author: Potenza MN; Voon V; Weintraub D;
Institution: Department of Psychiatry, Yale University School of Medicine, Connecticut Mental Health Center, New Haven, CT 06519, USA. marc.potenza@yale.edu
Journal: Nat Clin Pract Neurol. 2007 Dec;3(12):664-72.
Abstract URL: Click here to view abstract

48. Constant dopaminergic stimulation by transdermal delivery of dopaminergic drugs: a new treatment paradigm in Parkinson's disease.

Author: Steiger M;
Institution: Walton Centre for Neurology and Neurosurgery, NHS Trust, Liverpool, UK. malcolm.steiger@thewaltoncentre.nhs.uk
Journal: Eur J Neurol. 2008 Jan;15(1):6-15. Epub 2007 Nov 27.
Abstract URL: Click here to view abstract

49. Parkinson's disease: a genetic perspective.

Author: Belin AC; Westerlund M;
Institution: Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden. andrea.carmine.belin@ki.se
Journal: FEBS J. 2008 Apr;275(7):1377-83. Epub 2008 Feb 12.
Abstract URL: Click here to view abstract

50. Parkinson's disease: recent development in therapies for advanced disease with a focus on deep brain stimulation (DBS) and duodenal levodopa infusion.

Author: Sydow O;
Institution: Department of Neurology, Karolinska University Hospital, Stockholm, Sweden. olof.sydow@karolinska.se
Journal: FEBS J. 2008 Apr;275(7):1370-6. Epub 2008 Feb 12.
Abstract URL: Click here to view abstract

51. Parkinson's disease: clinical features and diagnosis.

Author: Jankovic J;
Institution: Department of Neurology, Parkinson's Disease Center and Movement Disorders Clinic, Baylor College of Medicine, 6550 Fannin, Suite 1801, Houston, Texas 77030-3498, USA. josephj@bcm.tmc.edu
Journal: J Neurol Neurosurg Psychiatry. 2008 Apr;79(4):368-76.
Abstract URL: Click here to view abstract

52. The safety of dopamine agonists in the treatment of Parkinson's disease.

Author: Bonuccelli U; Ceravolo R;
Institution: University of Pisa, Department of Neuroscience, Via Roma, 67 56100 Pisa, Italy. u.bonuccelli@med.unipi.it
Journal: Expert Opin Drug Saf. 2008 Mar;7(2):111-27.
Abstract URL: Click here to view abstract

53. Psychosis in Parkinson's disease: phenomenology, frequency, risk factors, and current understanding of pathophysiologic mechanisms.

Author: Fenelon G;
Institution: Department of Neurology, Henri-Mondor Hospital, Creteil, France. gilles.fenelon@hmn.aphp.fr
Journal: CNS Spectr. 2008 Mar;13(3 Suppl 4):18-25.
Abstract URL: Click here to view abstract

54. Sleep disturbances and Parkinson's disease.

Author: Friedman JH; Millman RP;
Institution: Neuro Health Parkinson's Disease and Movement Disorders, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA. joseph_friedman@Brown.edu
Journal: CNS Spectr. 2008 Mar;13(3 Suppl 4):12-7.
Abstract URL: Click here to view abstract

55. Sleep disorders associated with Parkinson's disease: role of dopamine, epidemiology, and clinical scales of assessment.

Author: Mehta SH; Morgan JC; Sethi KD;
Institution: Movement Disorders Program, Department of Neurology, Medical College of Georgia, Augusta, GA 30912, USA. shmehta@mcg.edu
Journal: CNS Spectr. 2008 Mar;13(3 Suppl 4):6-11.
Abstract URL: Click here to view abstract

56. Treatment options for non-motor symptoms in late-stage Parkinson's disease.

Author: Coelho M; Ferreira J; Rosa M; Sampaio C;
Institution: Neurological Clinical Research Unit, Institute of Molecular Medicine, Av. Professor Egas Moniz, 1649-028, Lisbon, Portugal. migcoelho2002@yahoo.es
Journal: Expert Opin Pharmacother. 2008 Mar;9(4):523-35.
Abstract URL: Click here to view abstract

57. Efficacy of electroconvulsive therapy in the treatment of nondepressed psychiatric illness in elderly patients: a review of the literature.

Author: Wilkins KM; Ostroff R; Tampi RR; Wilkins KM; Ostroff R; Tampi RR;
Institution: Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut, USA. kirsten.wilkins@yale.edu
Journal: J Geriatr Psychiatry Neurol. 2008 Mar;21(1):3-11.
Abstract URL: Click here to view abstract

58. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's disease.

Author: Horstink M; Tolosa E; Bonuccelli U; Deuschl G; Friedman A; Kanovsky P; Larsen JP; Lees A; Oertel W; Poewe W; Rascol O; Sampaio C;
Institution: Department of Neurology, Radboud University Medical Centre, Nijmegen, The Netherlands. m.horstink@neuro.umcn.nl
Journal: Eur J Neurol. 2006 Nov;13(11):1186-202.
Abstract URL: Click here to view abstract

59. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease.

Author: Horstink M; Tolosa E; Bonuccelli U; Deuschl G; Friedman A; Kanovsky P; Larsen JP; Lees A; Oertel W; Poewe W; Rascol O; Sampaio C;
Institution: Department of Neurology, Radboud University Medical Centre, Nijmegen, The Netherlands. m.horstink@neuro.umcn.nl
Journal: Eur J Neurol. 2006 Nov;13(11):1170-85.
Abstract URL: Click here to view abstract

60. New pharmacologic horizons in the treatment of Parkinson disease.

Author: Bonuccelli U; Del Dotto P; Bonuccelli U; Del Dotto P;
Institution: Department of Neuroscience, University of Pisa, Italy. u.bonuccelli@med.unipi.it
Journal: Neurology. 2006 Oct 10;67(7 Suppl 2):S30-8.
Abstract URL: Click here to view abstract

61. Novel pharmacological targets for the treatment of Parkinson's disease.

Author: Schapira AH; Bezard E; Brotchie J; Calon F; Collingridge GL; Ferger B; Hengerer B; Hirsch E; Jenner P; Le Novere N; Obeso JA; Schwarzschild MA; Spampinato U; Davidai G;
Institution: University Department of Clinical Neurosciences, Royal Free and University College Medical School, University College London, Rowland Hill Street, London NW3 2PF, UK. a.schapira@medsch.ucl.ac.uk
Journal: Nat Rev Drug Discov. 2006 Oct;5(10):845-54.
Abstract URL: Click here to view abstract

62. Rotigotine for the treatment of Parkinson's disease.

Author: Morgan JC; Sethi KD;
Institution: Movement Disorders Program, Department of Neurology, Medical College of Georgia,1429 Harper Street, HF-1121 Augusta, GA 30912, USA. jmorgan@mcg.edu
Journal: Expert Rev Neurother. 2006 Sep;6(9):1275-82.
Abstract URL: Click here to view abstract

63. Cognitive, affective, and psychiatric features of Parkinson's disease.

Author: Barbas NR;
Institution: Department of Neurology, University of Michigan, 1920 Taubman Center 0316, 1500 Medical Center Drive, Ann Arbor, MI 48109-0316, USA. nbarbas@med.umich.edu
Journal: Clin Geriatr Med. 2006 Nov;22(4):773-96, v-vi.
Abstract URL: Click here to view abstract

64. Medical management of advanced Parkinson's disease.

Author: Goudreau JL;
Institution: Department of Neurology and Department of Pharmacology and Toxicology, Michigan State University, East Lansing, MI 48842, USA. john.goudreau@ht.msu.edu
Journal: Clin Geriatr Med. 2006 Nov;22(4):753-72, v.
Abstract URL: Click here to view abstract

65. Parkinson's disease: background, diagnosis, and initial management.

Author: Albin RL;
Institution: Geriatrics Research, Education, and Clinical Center, Veterans Administration Medical Center, Ann Arbor, MI 48109-0585, USA. ralbin@umich.edu
Journal: Clin Geriatr Med. 2006 Nov;22(4):735-51, v.
Abstract URL: Click here to view abstract

66. Drug Insight: new drugs in development for Parkinson's disease.

Author: Colosimo C; Fabbrini G; Berardelli A;
Institution: University Department of Neurosciences University of Rome, La Sapienza, Italy. carlo.colosimo@uniroma1.it
Journal: Nat Clin Pract Neurol. 2006 Nov;2(11):600-10.
Abstract URL: Click here to view abstract

67. Tolcapone in the management of Parkinson's disease.

Author: Leegwater-Kim J; Waters C;
Institution: Columbia University Medical Center, Department of Neurology, Division of Movement Disorders, 710 W. 168th Street, New York, NY 10032, USA.
Journal: Expert Opin Pharmacother. 2006 Nov;7(16):2263-70.
Abstract URL: Click here to view abstract

68. Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson's disease.

Author: Nyholm D;
Institution: Department of Neuroscience, Neurology, Uppsala University Hospital, SE-75185, Uppsala, Sweden. dag.nyholm@neurologi.uu.se
Journal: Expert Rev Neurother. 2006 Oct;6(10):1403-11.
Abstract URL: Click here to view abstract

69. Parkinson's disease: diagnosis and treatment.

Author: Rao SS; Hofmann LA; Shakil A;
Institution: University of Texas Southwestern Medical School at Dallas Family Medicine Residency Program, Dallas, Texas 75390, USA. shobha.rao@utsouthwestern.edu
Journal: Am Fam Physician. 2006 Dec 15;74(12):2046-54.
Abstract URL: Click here to view abstract

70. Rasagiline (Azilect) for Parkinson's disease.

Author
Institution
Journal: Med Lett Drugs Ther. 2006 Dec 4;48(1249/1250):97-9.

71. Recognition and management of neuropsychiatric complications in Parkinson's disease.

Author: Ferreri F; Agbokou C; Gauthier S;
Institution: Alzheimer's Disease Research Unit, McGill Centre for Studies in Aging, Douglas Hospital, Verdun, Quebec, Canada.
Journal: CMAJ. 2006 Dec 5;175(12):1545-52.
Abstract URL: Click here to view abstract

72. Criteria for deep-brain stimulation in Parkinson's disease: review and analysis.

Author: Moro E; Lang AE;
Institution: University of Toronto, Department of Medicine, Movement Disorders Center, 399 Bathurst Street, McL7 402, Canada. elena.moro@uhn.on.ca
Journal: Expert Rev Neurother. 2006 Nov;6(11):1695-705.
Abstract URL: Click here to view abstract

73. Long-term care of Parkinson's disease. Strategies for managing "wearing off" symptom re-emergence and dyskinesias.

Author: Hauser RA;
Institution: Parkinson's Disease and Movement Disorders Center, National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, FL, USA.
Journal: Geriatrics. 2006 Sep;61(9):14-20.
Abstract URL: Click here to view abstract

74. Neuroprotective therapy in Parkinson disease.

Author: Chen S; Le W;
Institution: Institute of Neurology, Ruijin Hospital, Shanghai 2nd Medical University, Shanghai, China.
Journal: Am J Ther. 2006 Sep-Oct;13(5):445-57.
Abstract URL: Click here to view abstract

75. Emerging drugs for Parkinson's disease.

Author: Morgan JC; Sethi KD; Morgan JC; Sethi KD;
Institution: Medical College of Georgia, Movement Disorders Program, Department of Neurology, 1429 Harper Street, HF-1121, Augusta, GA 30912, USA. jmorgan@mcg.edu
Journal: Expert Opin Emerg Drugs. 2006 Sep;11(3):403-17.
Abstract URL: Click here to view abstract

76. Excessive daytime sleepiness and unintended sleep in Parkinson's disease.

Author: Rye DB;
Institution: Department of Neurology, Emory University School of Medicine, 101 Woodruff Circle, WMRB-Suite 6000, PO Drawer V, Atlanta, GA 30322, USA. drye@emory.edu
Journal: Curr Neurol Neurosci Rep. 2006 Mar;6(2):169-76.
Abstract URL: Click here to view abstract

77. Rotigotine: a novel dopamine agonist for the transdermal treatment of Parkinson's disease.

Author: Zareba G;
Institution: Department of Environmental Medicine, University of Rochester, School of Medicine and Dentistry, Rochester, New York 14642, USA. grazyna_zareba@urmc.rochester.edu
Journal: Drugs Today (Barc). 2006 Jan;42(1):21-8.
Abstract URL: Click here to view abstract

78. Non-motor symptoms of Parkinson's disease: diagnosis and management.

Author: Chaudhuri KR; Healy DG; Schapira AH;
Institution: Movement Disorders Unit, Kings College Hospital, Guy's King's and St Thomas' School of Medicine, London, UK. ray.chaudhuri@uhl.nhs.uk
Journal: Lancet Neurol. 2006 Mar;5(3):235-45.
Abstract URL: Click here to view abstract

79. Neural stimulation for Parkinson's disease: current therapies and future directions.

Author: Neimat JS; Hamani C; Lozano AM;
Institution: Toronto Western Hospital, Toronto, Ontario M5T 2S8, Canada. jneimat@gmail.com
Journal: Expert Rev Neurother. 2006 Jan;6(1):101-9.
Abstract URL: Click here to view abstract

80. Parkinson's disease management strategies.

Author: Rajput A; Rajput AH;
Institution: Royal University Hospital, Saskatchewan, S7N 0W8, Canada. rajputa@sask.usask.ca
Journal: Expert Rev Neurother. 2006 Jan;6(1):91-9.
Abstract URL: Click here to view abstract

81. Dopamine agonists in the treatment of Parkinson's disease.

Author: Bonuccelli U; Pavese N;
Institution: Department of Neuroscience, University of Pisa, (56126) Pisa, Italy. u.bonuccelli@med.unipi.it
Journal: Expert Rev Neurother. 2006 Jan;6(1):81-9.
Abstract URL: Click here to view abstract

82. Cholinesterase inhibitors for Parkinson's disease dementia.

Author: Maidment I; Fox C; Boustani M;
Institution: East Kent NHS and Social Care Partnership Trust, University of Kent, Trust HQ, Littlebourne Road, Canterbury, Kent, UK. ian.maidment@nhs.net
Journal: Cochrane Database Syst Rev. 2006 Jan 25;(1):CD004747.
Abstract URL: Click here to view abstract

83. Cell transplantation for patients with Parkinson's disease.

Author: Paul G;
Institution: Neuronal Survival Unit, Experimental Medical Sciences, Wallenberg Neurocentrum, University of Lund, BMC A10, 22184 Lund, Sweden. gesine.paul@mphy.lu.se
Journal: Handb Exp Pharmacol. 2006;(174):361-88.
Abstract URL: Click here to view abstract

84. Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.

Author: Pahwa R; Factor SA; Lyons KE; Ondo WG; Gronseth G; Bronte-Stewart H; Hallett M; Miyasaki J; Stevens J; Weiner WJ;
Institution: University of Kansas Medical Center, Kansas City, USA.
Journal: Neurology. 2006 Apr 11;66(7):983-95.
Abstract URL: Click here to view abstract

85. Psychosis in Parkinson's disease: case studies.

Author: Salter BC; Anderson KE; Weiner WJ;
Institution: Department of Neurology, University of Maryland School of Medicine, Baltimore, MD 21202, USA.
Journal: Neurol Clin. 2006 May;24(2):363-9.
Abstract URL: Click here to view abstract

86. Melanoma, Parkinson's disease and levodopa: causal or spurious link? A review of the literature.

Author: Zanetti R; Loria D; Rosso S;
Institution: Piedmont Cancer Registry, Center for Oncology, Turin, Italy. roberto.zanetti@cpo.it
Journal: Melanoma Res. 2006 Jun;16(3):201-6.
Abstract URL: Click here to view abstract

87. Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease.

Author: Olanow CW; Obeso JA; Stocchi F;
Institution: Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA. warren.olanow@mssm.edu
Journal: Nat Clin Pract Neurol. 2006 Jul;2(7):382-92.
Abstract URL: Click here to view abstract

88. A comprehensive approach to Parkinson's disease. How to manage fluctuating motor and nonmotor symptoms.

Author: Brunton S;
Institution: Cabarrus/Northeast Medical Center Family Medicine, Charlotte, North Carolina, USA. ozdoc@aol.com
Journal: Postgrad Med. 2006 Jun-Jul;119(1):55-64.
Abstract URL: Click here to view abstract

89. Treatment of advanced Parkinson's disease.

Author: Diamond A; Jankovic J;
Institution: Movement Disorder Clinic, Colorado Neurologic Institute, 701 East Hampden Ave. Suite 330 Englewood, CO 80113, USA. Neurodoc01@sbcglobal.net
Journal: Expert Rev Neurother. 2006 Aug;6(8):1181-97.
Abstract URL: Click here to view abstract

90. Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes.

Author: Kleiner-Fisman G; Herzog J; Fisman DN; Tamma F; Lyons KE; Pahwa R; Lang AE; Deuschl G;
Institution: Parkinson's Disease Research Education and Clinical Center, Philadelphia VA Hospital, Philadelphia, Pennsylvania 19104, USA. galit.kleiner-fisman@med.va.gov
Journal: Mov Disord. 2006 Jun;21 Suppl 14:S290-304.
Abstract URL: Click here to view abstract

91. Impulse control disorders in Parkinson's disease.

Author: Weintraub D; Potenza MN;
Institution: Department of Psychiatry, University of Pennsylvania, 3535 Market Street, Room 3003, Philadelphia, PA 19104, USA. weintrau@mail.med.upenn.edu
Journal: Curr Neurol Neurosci Rep. 2006 Jul;6(4):302-6.
Abstract URL: Click here to view abstract

92. Non-motor aspects of Parkinson's disease.

Author: Borek LL; Amick MM; Friedman JH;
Institution: Department of Geriatric Psychiatry, Brown University School of Medicine, Providence, RI, USA. Leolisa@yahoo.com
Journal: CNS Spectr. 2006 Jul;11(7):541-54.
Abstract URL: Click here to view abstract

93. Deep brain stimulation: neuropsychological and neuropsychiatric issues.

Author: Voon V; Kubu C; Krack P; Houeto JL; Troster AI;
Institution: Department of Psychiatry, Toronto Western Hospital, Toronto, Canada. voonv@ninds.nih.gov
Journal: Mov Disord. 2006 Jun;21 Suppl 14:S305-27.
Abstract URL: Click here to view abstract

94. Repetitive transcranial magnetic stimulation to improve mood and motor function in Parkinson's disease.

Author: Helmich RC; Siebner HR; Bakker M; Munchau A; Bloem BR;
Institution: Department of Neurology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
Journal: J Neurol Sci. 2006 Oct 25;248(1-2):84-96. Epub 2006 Jun 21.
Abstract URL: Click here to view abstract

95. The diagnosis of Parkinson's disease.

Author: Tolosa E; Wenning G; Poewe W;
Institution: Neurology Service, Hospital Clinic, University of Barcelona, Barcelona, Spain. etolosa@clinic.ub.es
Journal: Lancet Neurol. 2006 Jan;5(1):75-86.
Abstract URL: Click here to view abstract

96. The management of psychosis in movement disorder patients.

Author: Chou KL; Borek LL; Friedman JH;
Institution: Department of Clinical Neurosciences, Warren Alpert Medical School of Brown University, Providence, RI, USA. Kelvin_Chou@brown.edu
Journal: Expert Opin Pharmacother. 2007 May;8(7):935-43.
Abstract URL: Click here to view abstract

97. PD-related psychosis: pathophysiology with therapeutical strategies.

Author: Wolters ECh;
Institution: Department of Neurology, Research Institute Neurosciences Vrije Universiteit, VU University Medical Center, Amsterdam, The Netherlands. e.wolters@vumc.nl
Journal: J Neural Transm Suppl. 2006;(71):31-7.
Abstract URL: Click here to view abstract